Kocjan Maciej, Kosowski Michał, Mazurkiewicz Michalina, Muzyk Piotr, Nowakowski Krzysztof, Kawecki Jakub, Morawiec Beata, Kawecki Damian
2nd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland.
Biomedicines. 2024 Oct 1;12(10):2242. doi: 10.3390/biomedicines12102242.
Due to their very wide range of indications, anticoagulants are one of the most commonly used drug groups. Although these drugs are characterized by different mechanisms of action, the most common complication of their use is still bleeding episodes, the frequency of which depends largely on the clinical condition of the patient using such therapy. For this reason, to this day, the best method of preventing bleeding complications remains the assessment of bleeding risk using scales such as HAS-BLED. There are many reports in the literature assessing the occurrence of this type of complication after the use of drugs affecting the coagulation process, as well as many reports comparing individual groups of drugs with different mechanisms of action. However, there are still no clear guidelines that would indicate which group of anticoagulants should be preferred in particular groups of patients. The aim of our article is to summarize the data collected so far regarding the safety of using specific groups of anticoagulants and the frequency of bleeding complications after their use.
由于抗凝剂的适应证范围非常广泛，它们是最常用的药物类别之一。尽管这些药物具有不同的作用机制，但使用它们最常见的并发症仍然是出血事件，其发生频率在很大程度上取决于接受此类治疗的患者的临床状况。因此，迄今为止，预防出血并发症的最佳方法仍是使用如HAS - BLED等量表评估出血风险。文献中有许多报告评估了使用影响凝血过程的药物后此类并发症的发生情况，也有许多报告比较了具有不同作用机制的各个药物组。然而，仍然没有明确的指南表明在特定患者群体中应优先选择哪一类抗凝剂。我们这篇文章的目的是总结迄今为止收集到的关于使用特定类别抗凝剂的安全性及其使用后出血并发症发生频率的数据。
